US2002020636A1PendingUtilityA1

Delivery of unstable pharmaceuticals

Priority: Dec 20, 1999Filed: Dec 15, 2000Published: Feb 21, 2002
Est. expiryDec 20, 2019(expired)· nominal 20-yr term from priority
B65D 51/285A61J 1/2027A61J 1/2093B65D 81/32
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A device for the delivery of unstable pharmaceutical preparations is disclosed. The device includes an upper container for receiving a first component of the preparation and a lower container for receiving a second component of the preparation. The first and second components are unstable when mixed. Advantageous preparations for use in the device are also disclosed.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A device for the delivery of a pharmaceutical preparation having a first component and a second component, comprising: 
 an upper container for receiving said first component and having a bottom, said first component comprising an unstable anti-infective agent;    a lower container for receiving a second component, said second component comprising a liquid carrier for said first component;    a tubular sleeve movably disposed within said upper container; and    a cap rotationally coupled to said upper container;    wherein when said cap is screwed onto said upper container, said tubular sleeve tears said bottom of said upper container to place said first component in communication with said second component.    
     
     
         2 . The device of  claim 1  wherein said first component comprises a liquid.  
     
     
         3 . The device of  claim 1  wherein said first component comprises a powder.  
     
     
         4 . The device of  claim 1  wherein said liquid carrier comprises a pharmaceutically active agent.  
     
     
         5 . The device of  claim 1  wherein said second component comprises polysorbate 80 and benzalkonium chloride, and wherein said polysorbate 80 minimizes any instability of said benzalkonium chloride due to gamma radiation and allows said device to be sterilized by gamma radiation.  
     
     
         6 . device for the delivery of a pharmaceutical preparation having a first component and a second component, comprising: 
 an upper container for receiving a first component and having a bottom, said first component comprising a first pharmaceutically active agent;    a lower container for receiving a second component unstable in said first component, said second component comprising a second pharmaceutically active agent;    a tubular sleeve movably disposed within said upper container; and    a cap rotationally coupled to said upper container;    wherein when said cap is screwed onto said upper container, said tubular sleeve tears said bottom of said upper container to place said first component in communication with said second component.    
     
     
         7 . The device of  claim 6  wherein said first pharmaceutically active agent comprises an anti-inflammatory agent, and said second pharmaceutically active agent comprises an anti-infective agent.  
     
     
         8 . The device of  claim 6  wherein said first pharmaceutically active agent comprises an anti-infective agent, and said second pharmaceutically active agent comprises an anti-inflammatory agent.  
     
     
         9 . The device of  claim 6  wherein said first component and said second component are liquids.  
     
     
         10 . The device of  claim 6  wherein said first component is a liquid and second second component is a powder.  
     
     
         11 . The device of  claim 6  wherein said first component is a powder and said second component is a liquid.  
     
     
         12 . The device of  claim 1  wherein said unstable anti-infective agent comprises an antibiotic selected from the group consisting of trimethoprims, polymyxin B sulfate, beta-lactams, oxazolidinones, macrolides, keytolides, tetracyclines, and pristinomycins.

Join the waitlist — get patent alerts

Track US2002020636A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.